Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364552 | 0.90 | CHRM3 (0.47) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL1364554 | 0.81 | CHRM3 (0.48) | CHRM3 | |
| SCHEMBL4049340 | 0.76 | MGLL (0.43) | CHRM3 | |
| SCHEMBL4218341 | 0.74 | CHRM3 (0.67) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4049044 | 0.74 | KCNH2 (0.48) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4215941 | 0.74 | CHRM3 (0.79) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4211535 | 0.74 | CHRM3 (0.65) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL3402039 | 0.72 | CHRM3 (0.56) | CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL3399242 | 0.72 | CHRM3 (0.54) | CHRM3CHRM2CHRM1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4216002 | 0.71 | CHRM3 (0.74) | CHRM3CHRM2CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249647-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009100168-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4B, PDE4A, CHRM4 | CHRM3 5/4885CHRM2 4/4885CHRM1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.